Mercer International Stock Surges 45% on C$20 Million Canada Funding 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Toyota Global Sales Fall as China Demand Slumps 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
(4) - EconoTimes)
Add as a preferred source on Google
BERKELEY, Calif., April 03, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on March 29, 2018 the Compensation Committee of Dynavax’s Board of Directors approved the grant of (i) inducement stock options to purchase an aggregate 114,000 shares of common stock and (ii) an inducement restricted stock unit award covering 1,800 shares of common stock, to nine new employees. These awards were granted pursuant to the Dynavax Technologies Corporation Inducement Plan, as an inducement material to the new employees entering into employment with Dynavax, in accordance with the NASDAQ Listing Rule 5635(c)(4).
Dynavax granted stock options to purchase shares of Dynavax’s common stock to the new employees with an exercise price of $18.80 per share, the closing price of Dynavax’s common stock on April 2, 2018, the effective date of such grants. The stock options and restricted stock units vest as follows: (a) the stock options vest over a three-year period, with one-third of the shares subject to such awards vesting on the first anniversary of the award’s vesting commencement date, and 1/36th of the shares subject to such awards vesting monthly thereafter, subject to each such employee’s continued employment with Dynavax on such vesting dates; and (b) the restricted stock units vest on April 2, 2018, the effective date of such award.
Dynavax is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).
About Dynavax
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.
Contact:
David Burke
Director, Investor Relations & Corporate Communications
510.665.7269
[email protected]
